嘉應制藥(002198.SZ):陳泳洪等三位股東終止與林少斌的股份轉讓協議
格隆匯11月2日丨嘉應制藥(002198.SZ)公佈,公司於2021年11月2日收到公司股東陳泳洪、黃智勇、黃利兵(以下簡稱“三位股東”)的通知,獲悉三位股東與林少斌已就終止協議轉讓公司股份事宜協商達成一致意見,於2021年11月1日共同簽署了《<陳泳洪、黃智勇、黃利兵與林少斌關於廣東嘉應制藥股份有限公司之股份轉讓協議>之解除協議》。
截至本公吿披露日,上述三位股東擬轉讓的股份尚未在深圳證券交易所辦理股份協議轉讓確認意見書,也未在中國證券登記結算有限責任公司深圳分公司辦理過户登記手續。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.